Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 4
2014 2
2015 3
2016 3
2017 7
2018 10
2019 13
2020 16
2021 17
2022 23
2023 17
2024 6

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35701215

101 results

Results by year

Filters applied: . Clear all
Page 1
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, Hendlisz A, Flamen P, Karfis I. Mileva M, et al. J Nucl Med. 2024 Feb 1;65(2):236-244. doi: 10.2967/jnumed.123.265987. J Nucl Med. 2024. PMID: 38164576 Clinical Trial.
Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects.
Parghane RV, Mitra A, Bannore TU, Rakshit S, Banerjee S, Basu S. Parghane RV, et al. World J Nucl Med. 2020 Oct 2;20(1):73-81. doi: 10.4103/wjnm.WJNM_52_20. eCollection 2021 Jan-Mar. World J Nucl Med. 2020. PMID: 33850492 Free PMC article.
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors.
Parghane RV, Talole S, Basu S. Parghane RV, et al. World J Nucl Med. 2019 Apr-Jun;18(2):160-170. doi: 10.4103/wjnm.WJNM_39_18. World J Nucl Med. 2019. PMID: 31040748 Free PMC article.
101 results